Updates are available Correction dated 2025-05-30
Click to view Correction: https://doi.org/10.1007/s00259-025-07369-x
-
Authors
Pascual, Thomas N. B. https://orcid.org/0000-0001-6444-7803
Paez, Diana https://orcid.org/0000-0001-9268-0979
Iagaru, Andrei https://orcid.org/0000-0003-0839-5329
Gnanasegaran, Gopi https://orcid.org/0000-0002-4617-9013
Lee, Sze Ting https://orcid.org/0000-0001-8641-456X
Sathekge, Mike https://orcid.org/0000-0002-2806-0625
Buatti, John M. https://orcid.org/0000-0001-8499-3721
Giammarile, Francesco https://orcid.org/0000-0002-0550-7893
Al-Ibraheem, Akram https://orcid.org/0000-0002-0978-4716
Pardo, Manuela Arevalo
Baum, Richard P. https://orcid.org/0000-0003-1723-0075
De Bari, Berardino https://orcid.org/0000-0003-0117-3360
Ben-Haim, Simona https://orcid.org/0000-0002-6111-1826
Blay, Jean-Yves https://orcid.org/0000-0001-7190-120X
Brink, Anita https://orcid.org/0000-0001-8658-2379
Estrada-Lobato, Enrique https://orcid.org/0000-0002-2597-8609
Fanti, Stefano https://orcid.org/0000-0003-1486-2624
Golubic, Anja Tea https://orcid.org/0000-0002-1113-3840
Hatazawa, Jun https://orcid.org/0000-0003-1425-0521
Israel, Ora https://orcid.org/0000-0001-6545-0924
Kiess, Ana https://orcid.org/0000-0001-6928-3852
Knoll, Peter https://orcid.org/0000-0002-1249-922X
Kunikowska, Jolanta
Louw, Lizette https://orcid.org/0000-0002-4146-2485
Mariani, Giuliano https://orcid.org/0000-0002-1900-4488
Mirzaei, Siroos https://orcid.org/0000-0003-2861-6811
Orellana, Pilar https://orcid.org/0000-0001-7743-5836
Prior, John O. https://orcid.org/0000-0003-1429-1374
Urbain, Jean-Luc
Vichare, Shrikant https://orcid.org/0009-0004-5854-0963
Vinjamuri, Sobhan https://orcid.org/0000-0003-3571-3273
Virgolini, Irene https://orcid.org/0000-0001-7097-6170
Scott, Andrew M. https://orcid.org/0000-0002-6656-295X
-
Funding
Funding for this research was provided by:
La Trobe University
- License Information
-
More Information
Article History
Received: 11 December 2023
Accepted: 13 February 2024
First Online: 8 March 2024
Change Date: 30 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-025-07369-x
Declarations
:
: AI reports scientific advisory boards for Alpha9Tx, Clarity Pharmaceuticals, Radionetics Oncology; research grants from GE Healthcare and Novartis; consulting with Novartis, Progenics Pharmaceuticals, and study steering committee for Novartis. GG has received speaker fee from Advanced Accelerator Application. RPB is an advisor to 3B Pharmaceuticals, ITM, Full Life Technologies, Sinotau, Jiangsu Huayi Technology, and Telix Pharmaceuticals. OI is a consultant for General Electric Healthcare. AK reports Institutional clinical research funding from Bayer, Novartis, Merck, and Lantheus; unpaid steering committee and advisory boards for Novartis; unpaid speaker (one event) for POINT. SV reports funding for educational lectures from Bayer, AAA/Novartis, Astellas. AMS reports trial funding from EMD Serono, ITM, Telix Pharmaceuticals, AVID Radiopharmaceuticals, Fusion Pharmaceuticals, and Cyclotek; research funding from Medimmune, AVID Radiopharmaceuticals, Adalta, Antengene, Humanigen, Telix Pharmaceuticals and Theramyc; and advisory boards of Imagion and ImmunOs. The other authors report no relevant financial or non-financial interests to disclose.
